期刊文献+

对伴高凝状态的恶性肿瘤患者进行抗凝联合化疗的临床观察 预览 被引量:6

Clinical observation of anticoagulation combined chemotherapy in the treatment of malignant tumor patients with hypercoagulable state
在线阅读 下载PDF
分享 导出
摘要 目的:观察伴高凝状态的恶性肿瘤患者进行抗凝联合化疗的临床疗效。方法:对44例伴高凝状态恶性肿瘤患者进行抗凝加化疗,设为治疗组,给予一线标准方案化疗,同时给予低分子肝素钙6000U并伴随化疗,1次/d,皮下注射,阿司匹林100mgpo,1次/d,21~28d为1个周期,4个周期为1个疗程。对照组患者单独采用一线标准方案化疗。结果:治疗组和对照组有效率分别为22.7%和18.2%,两组比较,差异无统计学意义(P〉0.05);两组中位生存期(MST)分别为30.2个月和29.2个月,两组比较,差异无统计学意义(P〉0.05);治疗组和对照组KPS改善率分别为63.6%和36.4%,两组比较,差异有统计学意义(P〈0.05)。两组毒性反应基本相同。结论:伴高凝状态恶性肿瘤患者进行化疗时加抗凝治疗,效果较好,值得临床使用。 Objective:To observe the clinical effect of anticoagulation combined chemotherapy in the treatment of malignant tumor patients with hypercoagulable state.Methods:44 malignant tumor patients with hypercoagulable state were enrolled into the study.They were accepted the treatment of the first standard chemotherapy and anticoagulation.The treat ment of anticoagulation included low-molecular-weight heparin calcium 6 000 U ih following the chemotherapy and asprin 100 mg po,qd,the treatment was repeated every 21-28 days.After 4 cycles of chemotherapy,the efficacy and toxicity were evaluated.The other 44 patients of the control group were only accepted the first standard chemotherapy.Results:The efficacious rates were 22.7%(treatment group) and 18.2%(control group),there was no significant difference(P〈0.05).The median survival time(MST) of the two groups were 30.2 months and 29.2 months,there was no significant difference(P 0.05).The KPS improvement rate of the two groups were 63.6% and 36.4%,there was a significant difference(P〈0.05).The toxicity of the two groups were almost close.Conclusion:It's benefit from anticoagulation combined chemotherapy for the malignant tumor patients with hypercoagulable state.It's worthy of promotion.
作者 杨耀昆 张跃臣 王俭明 YANG Yaokun,ZHANG Yuechen,WANG Jianming(Department of Medical Oncology,the Second People's Hospital of Fuxin City,Fuxin 123000,China)
出处 《中国医药导报》 2010年第30期 28-29,共2页 China Medical Herald
关键词 恶性肿瘤 高凝状态 抗凝治疗 化疗 Malignant tumor Hypercoagulable state Anticoagulation Chemotherapy
作者简介 杨耀昆(1972-),男,副主任医师,大学本科,主要从事肿瘤内科工作。
  • 相关文献

参考文献7

  • 1潘磊,王勇,孙越,邓新力,经鼻无创正压通气治疗阻塞性睡眠呼吸暂停综合征血栓前状态效果评价[J].中国实用内科杂志,2006,26(7):1015-1017. 被引量:18
  • 2高文斌等主编,.肿瘤并发症的诊断与治疗[M].北京:人民军医出版社,2009:487.
  • 3van Marion AM,Auwerda JJ,Minnema MC,et al.Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis[J].Thromb Haemost,2005,94(6):1341-1343. 被引量:1
  • 4Pihusch V,Pihusch M,Penovici M,et al.Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in venoocclusive disease following hematopoetic stem cell transplantation[J].2005,116(3):233-240. 被引量:1
  • 5Cohen SA,Trikha M,Mascelli MA.Potential future clinical applications for the GP Ⅱb/Ⅲ a antagonist,abciximab in thrombosis,vascular and oncological indications[J].Pathol Oncol Res,2000,6(3):163-174. 被引量:1
  • 6王奇璐编,.肿瘤科主治医生873问[M].北京:中国协和医科大学出版社,2006.
  • 7白丽萍,门剑龙,恶性转移瘤患者高凝状态的研究[J].中国慢性病预防与控制,2006,14(4):241-242. 被引量:18

二级参考文献10

共引文献32

同被引文献62

引证文献6

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈